Focusing on cytokine and inflammatory mediators within the whole signalling pathways between TNF-α, TRAIL, also known as Apo2 ligand, and NF-κB provides a comprehensive understanding of this complex pathway as it relates to breast and colon cancer and offers insight into potential therapeutic agents. This evidence concerns the gene NFKB1 and malignant colon neoplasm.